Di pɔsin we yu lɛk, sɔntɛm yu mama, papa, grani ɔ granpa, gɛt Alzaima sik? Wi ɔl no di sɔri ɛn nɔ ebul fɔ ɛp wisɛf we wi nɔ de mɛmba smɔl smɔl ɛn fɔgɛt di fes dɛn we wi sabi. Alzaima sik na rili wan sik wae kin mek yu nɔr de mɛmba fayn, yu bren pwɛl ɛn ivin day. Pan ɔl we no mɛrɛsin nɔ de fɔ dis sik, mɛrɛsin dɛn de we kin mek i slo ɛn gi sɔm kayn fridɔm to di pɔsin. Tide wi go tɔk bɔt wan pan dɛn kayn spɛshal klas ya fɔ drɔgs. Dat na NMDA Risɛptɔ Antagɔnis dɛn . Pan ɔl we di nem kɔmplikt smɔl, lɛ wi ɔndastand am simpul wan.
Wan smɔl kemikal stori we kin apin na di bren
Wi bren na wɔndaful ples. i gεt bכku bilyan nεv sεl dεm, כ `nyurכn`. Dɛn sɛl ya de prosɛs di infɔmeshɔn, mɛmba infɔmeshɔn, ɛn tɛl ɔda pat dɛn na di bɔdi wetin fɔ du bay we dɛn de sɛn ilɛktrik ɛn kemikal signal bak ɛn go to dɛnsɛf.
wi kכl di mεsenja dεm we de kכri dεn kεmikכl signal dεm `nyurotransmitta`. Wan pan dɛn mɛsenja dɛn de na `glutamate` .
Jɔs tink bɔt glutamate as bot we de kɛr mɛsej frɔm wan nɛv sɛl to ɔda wan. Dis bot nid spɛshal dok fɔ go na di ɔda sɛl ɛn dok. dat dכk na in wi kכl di NMDA rεsεpכta (`N-methyl-D-aspartate` rεsεpכta. we di bot we dεn kכl glutamate de atak dis NMDA pכt, i de sεnd כda imכtant tin we dεn kכl `kalsiכm` insay di sεl. Dis kalsiכm na in de komplit da mεsej de εn i de εp wi fכ lan εn mεmba sכmtin. Dis na nכmal prכsεs insay hεlty bren.
So wetin kin apin pan Alzaima sik?
Insay pɔsin we gɛt Alzaima in bren sɛl dɛn , tumɔs glutamate kin bigin fɔ mek . Wetin kin apin na dat tumɔs kalsiɔm kin flɔ insay dɛn nɛv sɛl dɛn de. Imajin wetin go apin if yu ful-ɔp wata tank wit tumɔs wata? I kin ful-ɔp. Semweso, we tumɔs kalsiɔm gɛda insay di sɛl dɛn, dɛn sɛl dɛn de kin bigin fɔ pwɛl. Dis damej na wae de mek yu gɛt mɔr sik wae de kam wit Alzaima smɔl smɔl.
Na dis na aw NMDA Risεptor Antagonist dεm de εp
di klas fכ dכg dεm we dεn kכl NMDA rεsεpכta antagonist de wok bay we i de ridyus di nכmba כf ples dεm we dεn εkstra glutamεyt bot dεm kin dכk na di NMDA rεsεpכta. Dat min se di drɔg de blok sɔm pan di pɔt dɛn. Bɔt di tin we impɔtant pas ɔl na dat dɛn drɔgs ya kin mek impɔtant mɛsej dɛn flɔ . dat min se, dεn de כnli kכntro di dεstruktiv influx fכ kalsiכm we nכ de mek nכ big disrupshכn pan di nכmal fכnshכn na di bren. Dis kin mek di nεv sεl dεm dכn pwεl εn i kin kכntro di spid we di sik de spid.
We dɛn de trit di sik we dɛn kɔl Alzaima, bɔku tɛm dɔktɔ dɛn kin yuz mɛrɛsin dɛn we de tɔch ɔda nyurotransmit we dɛn kɔl asɛtilkolin. bכt NMDA rεsεpכta antagonist dεm na imכtant klas כf drog dεm we de wok difrεn we.
di men NMDA risεptor antagonist we dεn apruv naw fכ trit Alzaima sik na memantine (brand nem `Namenda XR`). Bɔrku tɛm na dɔktɔ dɛn kin gi am fɔ di stej dɛm we de na di sik we smɔl to we i rili bad. sכmtεm, dεn kin gi mεmantin in kכmbaynshכn wit di `cholinesterase inhibitors` we wi bin dכn mεnshכn bifo, we de inkrεs di asetilkolin lεvεl dεm. Dis kin mek sɔm sik pipul dɛn gɛt bɛtɛ rizɔlt.
Bɔt mɛmba se dɛn mɛrɛsin ya nɔ de wok di sem we fɔ ɔlman.
Lɛ wi no bak bɔt di bad tin dɛn we kin apin to wi.
Lɛk ɔl di mɛrɛsin dɛn, dis wan kin gɛt smɔl smɔl sayd ɛfɛkt dɛn.
- Diziz na di sayn we kin apin pas ɔl.
- Apat frɔm dat, tin dɛn lɛk ed we de at ɛn kɔnstipɛshɔn kin apin bak.
- Na smɔl tɛm nɔmɔ, i kin mek pɔsin kɔnfyus na di bren .
If yu ɔ yu pɔsin gɛt ɛni wan pan dɛn tin ya, yu fɔ tɛl yu dɔktɔ wantɛm wantɛm . I nɔ go ɛva fayn fɔ stɔp fɔ tek mɛrɛsin ɔ chenj di doz fɔ yusɛf.
Ɔda drɔgs dɛn we de na dis famili ɛn aw dɛn de yuz dɛn
כda dכg dεm de na dis famili we dεn kכl NMDA rεsεptכr antagonist. Sɔm pan dɛn wi kin si na ɛvride layf. Sɔm kin denja smɔl, ɛn dɛn kin yuz dɛn bad bad wan as drɔgs. Sayɛnsman dɛn de du risach bak bɔt di bɛnifit dɛn we dis klas mɛrɛsin kin gi fɔ ɔda sik dɛn we kin kam pan pɔsin in nyuro, lɛk di sik we dɛn kɔl Parkinson’s disease ɛn ALS (amyotrophic lateral sclerosis).
Lɛ wi lan mɔ bɔt am frɔm di tebul we de dɔŋ ya.
| Di Nem fɔ Drug | Men yus | Impɔtant pɔynt dɛn ɛn risk dɛn |
|---|---|---|
| Dɛkstromɛtɔrfan we dɛn kɔl | I de insay kɔf srɔp. | Jɛnɛral wan sef, bɔt i kin denja if dɛn tek am wit bɔku dos. |
| Ketamin we dɛn kɔl | Wan mɛrɛsin we de mek pɔsin nɔ fil fayn (fɔ mɔtalman ɛn animal dɛn). | Dɛn kin yuz am fɔ pul pen we dɛn de du ɔpreshɔn. Bɔt dɛn bin de abuz am as "klɔb drɔg". I kin mek yu gɛt hallucinations ɛn fil se yu nɔ de nia di bɔdi. Risach de go bifo pan aw fɔ yuz am fɔ sik lɛk pwɛl hat. |
| Fɛnsiklidin (PCP) we dɛn kɔl . | Dɛn bin de yuz am bad bad wan as drɔgs. | Fɔs dɛn bin divɛlɔp am as anestetik, dɛn bin pul am fɔ yuz bikɔs ɔf di bad bad sayd ɛfɛkt dɛn (hallucinations, kɔnfyushɔn). Wan denja drɔg we dɛn kɔl "Angel Dust". I gɛt fɔ du wit fɛt-fɛt bihayvya. |
Mɛsej we dɛn kin kɛr go na os
- pan ɔl we dɛn nɔ kin ebul fɔ wɛl ɔl di sik we dɛn kɔl Alzaima, NMDA riseptɔ antagonist drɔgs lɛk mɛmantin kin ɛp fɔ manej di mɔdaret to siriɔs stej dɛm na di sik bay we dɛn de ridyus di damej pan di bren sɛl dɛm.
- Dɛn drɔgs ya de wok bay we dɛn de protɛkt di nerve cells frɔm di glutamate we pasmak na di bren.
- Jɔs lɛk ɛni mɛrɛsin, sayd ɛfɛkt lɛk diziz kin apin. Tɔk bɔt dis wit yu dɔktɔ ɔltɛm. Nɔ ɛva chenj di doz ɔ stɔp fɔ tek di mɛrɛsin fɔ yusɛf.
- Dis klas ɔf drɔgs, lɛk Ketamine ɛn PCP, dɛn kin yuz am bad bad wan as nakotik ɛn dɛn kin rili denja. Big difrɛns de bitwin dɛn tin ya ɛn di mɛrɛsin dɛn we dɛn kin gi fɔ sik we dɛn kɔl Alzaima.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt